2 research outputs found
ΠΠΏΡΠΈΠΌΡΠ·Π°ΡΡΡ Π»ΡΠΊΡΠ²Π°Π½Π½Ρ Π²Π΅Π³Π΅ΡΠΎ-ΡΡΠ΄ΠΈΠ½Π½ΠΈΡ Ρ ΠΏΡΠΈΡ ΠΎΠ½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ ΠΏΠΎΡΡΡΠ΅Π½Ρ ΠΊΠ»ΡΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ
The article presents data on a study of transdermal therapeutic system with 600 mkg ethinylestradiol and 6000 mkg norelgestromin, which was used for removal vasomotor and neuropsychiatric disorders of severe and middle course of climacteric syndrome.Purpose: to assess the effectiveness of influence of transdermal therapeutic system with 600 mkg ethinylestradiol and 6000 mkg norelgestromin for vasomotor and neuropsychiatric disorders of severe and middle climacteric syndrome.Materials and methods. 103 women of postmenopausal age with severe and middle climacteric disorders were under observation: 65 of them were included into the main group, 38 β the comparison group. Severity stage of climacteric manifestation was determined according to menopause rating scale (MRS) before treatment and a month after treatment. Women of the main group were offered to treat climacteric disorders with TTS, which contains 600 mkg ethinylestradiol and 6000 mkg norelgestromin, in regime 1 patch per 1 month. Traditional MHT preparation was prescribed to the women of the comparison group, this drug contains 1mg ethinylestradiol and 5 mg dydrohesteron, per os route in uninterrupted regime.Results. It was found reduction of vegetative, vascular and neuropsychiatric menopausal symptoms and total index of menopause from 25.9 Β± 1.2 to 8.2 Β± 0.9 β in the main group; and from 25.4 Β± 1.6 to 9.9 Β± 1.2 β in the comparison group. Reliable difference (p < 0.05) was found out after treatment between indexes of the main and comparison groups according to such criteria, as: hot flashes, sleeping disorders, joint and muscle complaints, depression, anxiety. These indexes were mush better in the main group.Conclusions. During treatment of severe and middle climacteric syndrome with TTS, which contains 600 mkg ethinylestradiol and 6000 mkg norelgestromin (Evra plaster), rapid and durable correction of vegetative, vascular and neuropsychiatric climacteric disorders was found out. Reliable reduction of total index of menopause in a month after treatment by 68.3 % from the first index (in the comparison group β 61 %) allows to recommend TTS with ethinylestradiol and norelgestromin as independent correction method for severe and middle climacteric disorders tratment.Π ΠΎΡΠ½ΠΎΠ²Ρ ΡΡΠ°ΡΡΠΈ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ°Π½ΡΠ΄Π΅ΡΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠ΅ΠΉ 600 ΠΌΠΊΠ³ ΡΡΠΈΠ½ΠΈΠ»ΡΡΡΡΠ°Π΄ΠΈΠΎΠ»Π° ΠΈ 6000 ΠΌΠΊΠ³ Π½ΠΎΡΡΠ»Π³Π΅ΡΡΡΠΎΠΌΠΈΠ½Π°, ΠΊΠΎΡΠΎΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π΄Π»Ρ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΡ Π²Π΅Π³Π΅ΡΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΈ ΠΏΡΠΈΡ
ΠΎΠ½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΡΡΠΆΡΠ»ΠΎΠ³ΠΎ ΠΈ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΊΠ»ΠΈΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°.Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ β ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π»ΠΈΡΠ½ΠΈΡ Π’Π’Π‘, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠ΅ΠΉ 600 ΠΌΠΊΠ³ ΡΡΠΈΠ½ΠΈΠ»ΡΡΡΡΠ°Π΄ΠΈΠΎΠ»Π° ΠΈ 6000 ΠΌΠΊΠ³ Π½ΠΎΡΡΠ»Π³Π΅ΡΡΡΠΎΠΌΠΈΠ½Π°, Π½Π° ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π²Π΅Π³Π΅ΡΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΈ ΠΏΡΠΈΡ
ΠΎΠ½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΡΡΠΆΡΠ»ΡΠΌ ΠΈ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΊΠ»ΠΈΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΠ΄ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π½Π°Ρ
ΠΎΠ΄ΠΈΠ»ΠΎΡΡ 103 ΠΆΠ΅Π½ΡΠΈΠ½Ρ ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° Ρ ΡΡΠΆΡΠ»ΡΠΌΠΈ ΠΈ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΊΠ»ΠΈΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ: 65 β ΠΎΡΠ½ΠΎΠ²Π½Π°Ρ Π³ΡΡΠΏΠΏΠ°, 38 β Π³ΡΡΠΏΠΏΠ° ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ. Π‘ΡΠ΅ΠΏΠ΅Π½Ρ ΡΡΠΆΠ΅ΡΡΠΈ ΠΊΠ»ΠΈΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΏΠΎ ΡΠΊΠ°Π»Π΅ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Ρ MRS Π΄ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΡΠ΅ΡΠ΅Π· ΠΎΠ΄ΠΈΠ½ ΠΌΠ΅ΡΡΡ ΠΏΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΠ΅Π½ΡΠΈΠ½Π°ΠΌ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π’Π’Π‘, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠ΅ΠΉ 600 ΠΌΠΊΠ³ ΡΡΠΈΠ½ΠΈΠ»ΡΡΡΡΠ°Π΄ΠΈΠΎΠ»Π° ΠΈ 6000 ΠΌΠΊΠ³ Π½ΠΎΡΡΠ»Π³Π΅ΡΡΡΠΎΠΌΠΈΠ½Π°, Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΠΎΠ΄Π½Π° ΠΏΠ»Π°ΡΡΠΈΠ½ΠΊΠ° Π½Π° ΠΎΠ΄ΠΈΠ½ ΠΌΠ΅ΡΡΡ. ΠΠ΅Π½ΡΠΈΠ½Π°ΠΌ Π³ΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Π½Π°Π·Π½Π°ΡΠ°Π»ΠΈ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΡ ΠΠΠ’ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠΌ 1 ΠΌΠ³ ΡΡΡΡΠ°Π΄ΠΈΠΎΠ»Π° ΠΈ 5 ΠΌΠ³ Π΄ΠΈΠ΄ΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Π°, per os Π² Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΠΌ ΡΠ΅ΠΆΠΈΠΌΠ΅.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ° ΡΠΎΠ½Π΅ ΠΏΡΠΎΠ²Π΅Π΄ΡΠ½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π±Π°Π»ΡΠ½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ Π²Π΅Π³Π΅ΡΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΈ ΠΏΡΠΈΡ
ΠΎΠ½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Ρ ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠΌΠΌΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Ρ (Ρ 25,9 Β± 1,2 Π΄ΠΎ 8,2 Β± 0,9 β ΠΎΡΠ½ΠΎΠ²Π½Π°Ρ Π³ΡΡΠΏΠΏΠ°; Ρ 25,4 Β± 1,6 Π΄ΠΎ 9,9 Β± 1,2 β Π³ΡΡΠΏΠΏΠ° ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ). ΠΡΡΠ²Π»Π΅Π½Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½Π°Ρ ΡΠ°Π·Π½ΠΈΡΠ° (p < 0,05) ΠΏΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΈ Π³ΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΠΏΠΎ ΡΠ°ΠΊΠΈΠΌ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ: ΠΏΡΠΈΠ»ΠΈΠ²Ρ, ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ ΡΠΎ ΡΠ½ΠΎΠΌ, Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠ΅ Π½Π°ΡΡΡΠΎΠ΅Π½ΠΈΠ΅, ΠΎΡΡΡΠ΅Π½ΠΈΠ΅ Π±Π΅ΡΠΏΠΎΠΊΠΎΠΉΡΡΠ²Π°, ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈ ΠΏΡΠΈΡ
ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠΎΡΠ΅Π½ΠΈΠ΅, Π½Π΅ΠΏΡΠΈΡΡΠ½ΡΠ΅ ΠΎΡΡΡΠ΅Π½ΠΈΡ Π² ΡΡΡΡΠ°Π²Π°Ρ
ΠΈ ΠΌΡΡΡΠ°Ρ
. Π ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΡΡΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π±ΡΠ»ΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π»ΡΡΡΠ΅.ΠΡΠ²ΠΎΠ΄Ρ. ΠΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΡΡΠΆΡΠ»ΠΎΠ³ΠΎ ΠΈ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΊΠ»ΠΈΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π’Π’Π‘, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠ΅ΠΉ 600 ΠΌΠΊΠ³ ΡΡΠΈΠ½ΠΈΠ»ΡΡΡΡΠ°Π΄ΠΈΠΎΠ»Π° ΠΈ 6000 ΠΌΠΊΠ³ Π½ΠΎΡΡΠ»Π³Π΅ΡΡΡΠΎΠΌΠΈΠ½Π° (ΠΏΠ»Π°ΡΡΡΡΡ Evra), Π²ΡΡΠ²Π»Π΅Π½Π° Π±ΡΡΡΡΠ°Ρ ΠΈ ΡΡΠΎΠΉΠΊΠ°Ρ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡ Π²Π΅Π³Π΅ΡΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΈ ΠΏΡΠΈΡ
ΠΎΠ½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ². ΠΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠΌΠΌΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Ρ ΡΠ΅ΡΠ΅Π· 1 ΠΌΠ΅ΡΡΡ ΠΏΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π° 68,3 % (Π² Π³ΡΡΠΏΠΏΠ΅ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ β Π½Π° 61 %) ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°ΡΡ Π’Π’Π‘ Ρ ΡΡΠΈΠ½ΠΈΠ»ΡΡΡΡΠ°Π΄ΠΈΠΎΠ»ΠΎΠΌ ΠΈ Π½ΠΎΡΡΠ»Π³Π΅ΡΡΡΠΎΠΌΠΈΠ½ΠΎΠΌ ΠΊΠ°ΠΊ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ ΡΡΠΆΡΠ»ΡΡ
ΠΈ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΊΠ»ΠΈΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ.Β Π ΠΎΡΠ½ΠΎΠ²Ρ ΡΡΠ°ΡΡΡ β Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ ΡΡΠ°Π½ΡΠ΄Π΅ΡΠΌΠ°Π»ΡΠ½ΠΎΡ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½ΠΎΡ ΡΠΈΡΡΠ΅ΠΌΠΈ, ΡΠΎ ΠΌΡΡΡΠΈΡΡ 600 ΠΌΠΊΠ³ Π΅ΡΡΠ½ΡΠ»Π΅ΡΡΡΠ°Π΄ΡΠΎΠ»Ρ ΡΠ° 6000 ΠΌΠΊΠ³ Π½ΠΎΡΠ΅Π»Π³Π΅ΡΡΡΠΎΠΌΡΠ½Ρ, ΡΠΊΡ Π²ΠΈΠΊΠΎΡΠΈΡΡΠ°Π½ΠΎ Π΄Π»Ρ Π·ΠΌΠ΅Π½ΡΠ΅Π½Π½Ρ Π²Π΅Π³Π΅ΡΠΎ-ΡΡΠ΄ΠΈΠ½Π½ΠΈΡ
Ρ ΠΏΡΠΈΡ
ΠΎΠ½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
ΠΏΡΠΎΡΠ²ΡΠ² ΠΊΠ»ΡΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ Π²Π°ΠΆΠΊΠΎΠ³ΠΎ ΡΠ° ΡΠ΅ΡΠ΅Π΄Π½ΡΠΎΡ Π²Π°ΠΆΠΊΠΎΡΡΡ ΠΏΠ΅ΡΠ΅Π±ΡΠ³Ρ.ΠΠ΅ΡΠ° ΡΠΎΠ±ΠΎΡΠΈ β ΠΎΡΡΠ½ΠΈΡΠΈ Π΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡΡΡ Π²ΠΏΠ»ΠΈΠ²Ρ Π’Π’Π‘, ΡΠΎ ΠΌΡΡΡΠΈΡΡ 600 ΠΌΠΊΠ³ Π΅ΡΡΠ½ΡΠ»Π΅ΡΡΡΠ°Π΄ΡΠΎΠ»Ρ ΡΠ° 6000 ΠΌΠΊΠ³ Π½ΠΎΡΠ΅Π»Π³Π΅ΡΡΡΠΎΠΌΡΠ½Ρ, Π½Π° ΠΏΡΠΎΡΠ²ΠΈ Π²Π΅Π³Π΅ΡΠΎ-ΡΡΠ΄ΠΈΠ½Π½ΠΈΡ
Ρ ΠΏΡΠΈΡ
ΠΎΠ½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
ΠΏΠΎΡΡΡΠ΅Π½Ρ Ρ ΠΆΡΠ½ΠΎΠΊ ΡΠ· ΠΊΠ»ΡΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ½ΠΈΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ Π²Π°ΠΆΠΊΠΎΠ³ΠΎ ΡΠ° ΡΠ΅ΡΠ΅Π΄Π½ΡΠΎΡ Π²Π°ΠΆΠΊΠΎΡΡΡ ΠΏΠ΅ΡΠ΅Π±ΡΠ³Ρ.ΠΠ°ΡΠ΅ΡΡΠ°Π»ΠΈ ΡΠ° ΠΌΠ΅ΡΠΎΠ΄ΠΈ. ΠΡΠ΄ ΡΠΏΠΎΡΡΠ΅ΡΠ΅ΠΆΠ΅Π½Π½ΡΠΌ ΠΏΠ΅ΡΠ΅Π±ΡΠ²Π°Π»ΠΈ 103 ΠΆΡΠ½ΠΊΠΈ ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠΊΡ Π· ΠΊΠ»ΡΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ½ΠΈΠΌΠΈ ΠΏΠΎΡΡΡΠ΅Π½Π½ΡΠΌΠΈ Π²Π°ΠΆΠΊΠΎΠ³ΠΎ ΡΠ° ΡΠ΅ΡΠ΅Π΄Π½ΡΠΎΠ³ΠΎ ΠΏΠ΅ΡΠ΅Π±ΡΠ³Ρ: 65 β ΠΎΡΠ½ΠΎΠ²Π½Π° Π³ΡΡΠΏΠ°, 38 β Π³ΡΡΠΏΠ° ΠΏΠΎΡΡΠ²Π½ΡΠ½Π½Ρ. Π‘ΡΡΠΏΡΠ½Ρ Π²Π°ΠΆΠΊΠΎΡΡΡ ΠΊΠ»ΡΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ½ΠΈΡ
ΠΏΡΠΎΡΠ²ΡΠ² Π²ΠΈΠ·Π½Π°ΡΠ°Π»ΠΈ Π·Π° ΡΠΊΠ°Π»ΠΎΡ ΠΎΡΡΠ½ΡΠ²Π°Π½Π½Ρ ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·ΠΈ MRS Π΄ΠΎ Π»ΡΠΊΡΠ²Π°Π½Π½Ρ ΡΠ° ΡΠ΅ΡΠ΅Π· ΠΎΠ΄ΠΈΠ½ ΠΌΡΡΡΡΡ ΠΏΡΡΠ»Ρ Π»ΡΠΊΡΠ²Π°Π½Π½Ρ. ΠΡΠ½ΠΊΠ°ΠΌ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΡ Π³ΡΡΠΏΠΈ Π·Π°ΠΏΡΠΎΠΏΠΎΠ½ΠΎΠ²Π°Π½ΠΎ Π»ΡΠΊΡΠ²Π°Π½Π½Ρ ΠΊΠ»ΡΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ½ΠΈΡ
ΡΠΎΠ·Π»Π°Π΄ΡΠ² Π·Π° Π΄ΠΎΠΏΠΎΠΌΠΎΠ³ΠΎΡ Π’Π’Π‘, ΡΠΎ ΠΌΡΡΡΠΈΡΡ 600 ΠΌΠΊΠ³ Π΅ΡΡΠ½ΡΠ»Π΅ΡΡΡΠ°Π΄ΡΠΎΠ»Ρ ΡΠ° 6000 ΠΌΠΊΠ³ Π½ΠΎΡΠ΅Π»Π³Π΅ΡΡΡΠΎΠΌΡΠ½Ρ, Π² ΡΠ΅ΠΆΠΈΠΌΡ ΠΎΠ΄Π½Π° ΠΏΠ»Π°ΡΡΠΈΠ½ΠΊΠ° Π½Π° ΠΎΠ΄ΠΈΠ½ ΠΌΡΡΡΡΡ. ΠΡΠ½ΠΊΠ°ΠΌ Π³ΡΡΠΏΠΈ ΠΏΠΎΡΡΠ²Π½ΡΠ½Π½Ρ ΠΏΡΠΈΠ·Π½Π°ΡΠ°Π»ΠΈ ΡΡΠ°Π΄ΠΈΡΡΠΉΠ½Ρ ΠΠΠ’ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ, ΡΠΎ ΠΌΡΡΡΠΈΡΡ 1 ΠΌΠ³ Π΅ΡΡΡΠ°Π΄ΡΠΎΠ»Ρ ΡΠ° 5 ΠΌΠ³ Π΄ΡΠ΄ΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Ρ per os Π² Π±Π΅Π·ΠΏΠ΅ΡΠ΅ΡΠ²Π½ΠΎΠΌΡ ΡΠ΅ΠΆΠΈΠΌΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ. ΠΠ° ΡΠ»Ρ Π·Π΄ΡΠΉΡΠ½Π΅Π½ΠΎΠ³ΠΎ Π»ΡΠΊΡΠ²Π°Π½Π½Ρ Π²ΡΠ΄Π·Π½Π°ΡΠ΅Π½ΠΎ Π²ΡΡΠΎΠ³ΡΠ΄Π½Π΅ Π·Π½ΠΈΠΆΠ΅Π½Π½Ρ Π±Π°Π»ΡΠ½ΠΎΡ ΠΎΡΡΠ½ΠΊΠΈ Π²Π΅Π³Π΅ΡΠΎ-ΡΡΠ΄ΠΈΠ½Π½ΠΈΡ
ΡΠ° ΠΏΡΠΈΡ
ΠΎΠ½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΡΠ² ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·ΠΈ ΡΠ° Π·Π½ΠΈΠΆΠ΅Π½Π½Ρ ΡΡΠΌΠ°ΡΠ½ΠΎΠ³ΠΎ ΡΠ½Π΄Π΅ΠΊΡΡ ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·ΠΈ (Π· 25,9 Β± 1,2 Π΄ΠΎ 8,2 Β± 0,9 β ΠΎΡΠ½ΠΎΠ²Π½Π° Π³ΡΡΠΏΠ°; Π· 25,4 Β± 1,6 Π΄ΠΎ 9,9 Β± 1,2 β Π³ΡΡΠΏΠ° ΠΏΠΎΡΡΠ²Π½ΡΠ½Π½Ρ). ΠΠΈΡΠ²Π»Π΅Π½ΠΎ Π²ΡΡΠΎΠ³ΡΠ΄Π½Ρ ΡΡΠ·Π½ΠΈΡΡ (p < 0,05) ΠΏΡΡΠ»Ρ Π»ΡΠΊΡΠ²Π°Π½Π½Ρ ΠΌΡΠΆ ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΠ°ΠΌΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΡ Π³ΡΡΠΏΠΈ ΡΠ° Π³ΡΡΠΏΠΈ ΠΏΠΎΡΡΠ²Π½ΡΠ½Π½Ρ Π·Π° ΡΠ°ΠΊΠΈΠΌΠΈ ΠΊΡΠΈΡΠ΅ΡΡΡΠΌΠΈ: ΠΏΡΠΈΠΏΠ»ΠΈΠ²ΠΈ, ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΈ Π·Ρ ΡΠ½ΠΎΠΌ, Π΄Π΅ΠΏΡΠ΅ΡΠΈΠ²Π½ΠΈΠΉ Π½Π°ΡΡΡΡΠΉ, Π²ΡΠ΄ΡΡΡΡΡ ΡΡΡΡΠ±ΠΎΠ²Π°Π½ΠΎΡΡΡ, ΡΡΠ·ΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠ° ΠΏΡΠΈΡ
ΡΡΠ½ΠΎΠ³ΠΎ Π²ΠΈΡΠ½Π°ΠΆΠ΅Π½Π½Ρ, Π½Π΅ΠΏΡΠΈΡΠΌΠ½Ρ Π²ΡΠ΄ΡΡΡΡΡ Π² ΡΡΠ³Π»ΠΎΠ±Π°Ρ
Ρ ΠΌβΡΠ·Π°Ρ
. Π ΠΎΡΠ½ΠΎΠ²Π½ΡΠΉ Π³ΡΡΠΏΡ ΡΡ ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΠΈ Π±ΡΠ»ΠΈ Π·Π½Π°ΡΠ½ΠΎ ΠΊΡΠ°ΡΡ.ΠΠΈΡΠ½ΠΎΠ²ΠΊΠΈ. ΠΡΠΈ Π»ΡΠΊΡΠ²Π°Π½Π½Ρ ΠΊΠ»ΡΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ Π²Π°ΠΆΠΊΠΎΠ³ΠΎ ΡΠ° ΡΠ΅ΡΠ΅Π΄Π½ΡΠΎΠ³ΠΎ ΠΏΠ΅ΡΠ΅Π±ΡΠ³Ρ Π·Π° Π΄ΠΎΠΏΠΎΠΌΠΎΠ³ΠΎΡ TTC, ΡΠΎ ΠΌΡΡΡΠΈΡΡ 600 ΠΌΠΊΠ³ Π΅ΡΡΠ½ΡΠ»Π΅ΡΡΡΠ°Π΄ΡΠΎΠ»Ρ ΡΠ° 6000 ΠΌΠΊΠ³ Π½ΠΎΡΠ΅Π»Π³Π΅ΡΡΡΠΎΠΌΡΠ½Ρ (ΠΏΠ»Π°ΡΡΠΈΡ Evra), Π²ΠΈΡΠ²Π»Π΅Π½ΠΎ ΡΠ²ΠΈΠ΄ΠΊΡ ΡΠ° ΡΡΡΠΉΠΊΡ ΠΊΠΎΡΠ΅ΠΊΡΡΡ Π²Π΅Π³Π΅ΡΠΎ-ΡΡΠ΄ΠΈΠ½Π½ΠΈΡ
Ρ ΠΏΡΠΈΡ
ΠΎΠ½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
ΠΏΠΎΡΡΡΠ΅Π½Ρ. ΠΡΡΠΎΠ³ΡΠ΄Π½Π΅ Π·Π½ΠΈΠΆΠ΅Π½Π½Ρ ΡΡΠΌΠ°ΡΠ½ΠΎΠ³ΠΎ ΡΠ½Π΄Π΅ΠΊΡΡ ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·ΠΈ ΡΠ΅ΡΠ΅Π· ΠΎΠ΄ΠΈΠ½ ΠΌΡΡΡΡΡ ΠΏΡΡΠ»Ρ Π»ΡΠΊΡΠ²Π°Π½Π½Ρ Π½Π° 68,3 % (Ρ Π³ΡΡΠΏΡ ΠΏΠΎΡΡΠ²Π½ΡΠ½Π½Ρ β Π½Π° 61 %) Π΄Π°Ρ ΠΌΠΎΠΆΠ»ΠΈΠ²ΡΡΡΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΡΠ²Π°ΡΠΈ Π’Π’Π‘ Π· Π΅ΡΡΠ½ΡΠ»Π΅ΡΡΡΠ°Π΄ΡΠΎΠ»ΠΎΠΌ Ρ Π½ΠΎΡΠ΅Π»Π³Π΅ΡΡΡΠΎΠΌΡΠ½ΠΎΠΌ ΡΠΊ ΡΠ°ΠΌΠΎΡΡΡΠΉΠ½ΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΊΠΎΡΠ΅ΠΊΡΡΡ ΠΊΠ»ΡΠΌΠ°ΠΊΡΠ΅ΡΠΈΡΠ½ΠΈΡ
ΠΏΠΎΡΡΡΠ΅Π½Ρ Π²Π°ΠΆΠΊΠΎΠ³ΠΎ ΡΠ° ΡΠ΅ΡΠ΅Π΄Π½ΡΠΎΠ³ΠΎ ΡΡΡΠΏΠ΅Π½ΡΠ² Π²Π°ΠΆΠΊΠΎΡΡΡ.
Optimization of vasomotor and neuropsychiatric disorders treatment in climacteric syndrome
The article presents data on a study of transdermal therapeutic system with 600 mkg ethinylestradiol and 6000 mkg norelgestromin, which was used for removal vasomotor and neuropsychiatric disorders of severe and middle course of climacteric syndrome.
Purpose: to assess the effectiveness of influence of transdermal therapeutic system with 600 mkg ethinylestradiol and 6000 mkg norelgestromin for vasomotor and neuropsychiatric disorders of severe and middle climacteric syndrome.
Materials and methods. 103 women of postmenopausal age with severe and middle climacteric disorders were under observation: 65 of them were included into the main group, 38 β the comparison group. Severity stage of climacteric manifestation was determined according to menopause rating scale (MRS) before treatment and a month after treatment. Women of the main group were offered to treat climacteric disorders with TTS, which contains 600 mkg ethinylestradiol and 6000 mkg norelgestromin, in regime 1 patch per 1 month. Traditional MHT preparation was prescribed to the women of the comparison group, this drug contains 1mg ethinylestradiol and 5 mg dydrohesteron, per os route in uninterrupted regime.
Results. It was found reduction of vegetative, vascular and neuropsychiatric menopausal symptoms and total index of menopause from 25.9 Β± 1.2 to 8.2 Β± 0.9 β in the main group; and from 25.4 Β± 1.6 to 9.9 Β± 1.2 β in the comparison group. Reliable difference (p < 0.05) was found out after treatment between indexes of the main and comparison groups according to such criteria, as: hot flashes, sleeping disorders, joint and muscle complaints, depression, anxiety. These indexes were mush better in the main group.
Conclusions. During treatment of severe and middle climacteric syndrome with TTS, which contains 600 mkg ethinylestradiol and 6000 mkg norelgestromin (Evra plaster), rapid and durable correction of vegetative, vascular and neuropsychiatric climacteric disorders was found out. Reliable reduction of total index of menopause in a month after treatment by 68.3 % from the first index (in the comparison group β 61 %) allows to recommend TTS with ethinylestradiol and norelgestromin as independent correction method for severe and middle climacteric disorders tratment.
climacteric; psychoneuroses; ethinylestradiol; norelgestromi